Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival
Ethical considerations must include the impact on those who would carry children with modified genomes
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy